E1A

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

Retrieved on: 
Wednesday, April 10, 2024
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CREB-binding protein, NF2, Dexamethasone, FDA, MYC, TGI, Cancer, Bone marrow, Abdomen, Multiple myeloma, Mouse, MYB, Mesothelioma, EP300, Streets of Rage, Doctor of Philosophy, IND, Glomus tumor, TEAD, FMRP, Therapy, BRAF, CBP, Thomas Jefferson University, Patient, Neurofibromatosis, Hippopotamus, Neoplasm, Standard of care, AACR, E1A, IRF4

Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.

Key Points: 
  • Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.
  • Multiple myeloma is an aggressive blood cancer derived from malignant plasma cells in the bone marrow.
  • "We are excited to begin our Phase 1 study of OPN-6602 in patients with multiple myeloma this summer.
  • Malignant mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs or abdomen.

MHI Group to Participate in Vehicle-to-Infrastructure (V2I) Demonstration Test Program to Support Autonomous Highway Driving

Retrieved on: 
Thursday, October 6, 2022
Adoption, Quality of life, Communication, Efficiency, Transport, Mitsubishi Heavy Industries, MHI, Engineering, Carbon, E1A, ICT, Artificial intelligence, Company, Accident, Industry, CASE, Group, Business plan, Car, Safety, Road, Renewable energy

MHI Group will apply its diverse technologies in the test program and perform oversight of the V2I system, in preparation toward realizing tomorrow's automated driving society, especially as it relates to highway driving.

Key Points: 
  • MHI Group will apply its diverse technologies in the test program and perform oversight of the V2I system, in preparation toward realizing tomorrow's automated driving society, especially as it relates to highway driving.
  • Information in the forward direction undetectable by the onboard unit of an autonomous vehicle following another vehicle is transmitted to the rearward vehicle by V2I.
  • MHI-MS was selected to take part in the demonstration testing project, which is operated by NEXCO-Central, in an open call for participants.
  • Mitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense.